CinCor

CinCor is a biopharmaceutical company focused on the development of baxdrostat, a drug to treat hypertension and certain cardio-renal diseases.

Baxdrostat has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, to provide improved treatment for patients suffering from hypertension or high blood pressure, a condition affecting up to 20% of the world's population.

The company, founded by Jon Isaacsohn and Catherine Pearce, is looking to transform its promising clinical trials into market-ready pharmaceutical products. Once approved, CinCor's treatments will improve the lives of patients suffering from cardio-renal disease.